Article ID Journal Published Year Pages File Type
4353247 Progress in Neurobiology 2015 73 Pages PDF
Abstract

•Dyskinesia represents a debilitating complication of levodopa therapy for Parkinson's disease.•There appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system circuitry.•To propose a pathophysiological framework was timely and necessary.•This review thus provides an overview of our current understanding of dyskinesia.

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.

Related Topics
Life Sciences Neuroscience Neuroscience (General)
Authors
, , , , , , , , , , , , ,